Concepedia

David R. Valdecanas

DR

21

Publications

2.2K

Citations

21

H-Index

2004

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Mirna Therapeutics (United States)

First Hospital of China Medical University

Wellesley College

Pfizer (United States)

David R. Valdecanas is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, radiation oncology, and oncology.

Top concepts

Publications per year

2004–2021

21

Publications

21

PDL1 Regulation by p53 via miR-34

María Angélica Cortez, Cristina Ivan, David R. Valdecanas et al. · JNCI Journal of the National Cancer Institute · 2015 · 657 citations · Full text

Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy

Xiaohong Wang, Jonathan E. Schoenhals, Ailin Li et al. · Cancer Research · 2016 · 264 citations · Full text

Therapeutic Delivery of miR-200c Enhances Radiosensitivity in Lung Cancer

María Angélica Cortez, David R. Valdecanas, Xiaochun Zhang et al. · Molecular Therapy · 2014 · 192 citations · Full text

, , +14

Targeting Toll-like Receptor 9 with CpG Oligodeoxynucleotides Enhances Tumor Response to Fractionated Radiotherapy

Kathryn A. Mason, Hisanori Ariga, Robert E. Neal et al. · Clinical Cancer Research · 2005 · 151 citations · Full text

CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation

Luka Milas, Kathryn A. Mason, Hisanori Ariga et al. · Cancer Research · 2004 · 149 citations

Rows per page

1–5 of 21